home / stock / ate:cc / ate:cc news

ATE:CC News and Press, Antibe Therapeutics Inc. From 10/12/22

Stock Information
Company Name: Antibe Therapeutics Inc.
Stock Symbol: ATE:CC
Market: TSXC
Website: antibethera.com
Menu
ATE:CC ATE:CC Quote ATE:CC Short ATE:CC News ATE:CC Articles ATE:CC Message Board
Get ATE:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
ATE:CC - Antibe Provides Development Update for Otenaproxesul

- Patent application filed for improved formulation; strengthens IP protection to 2042 - Anticipated benefits include faster onset of action, lower doses - Phase II molar study no longer required; Phase II bunionectomy study on track for H1 2023 A...
ATE:CC - Antibe Announces Results of 2022 Annual Meeting

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”...

ATE:CC - Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

- Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target infl...

ATE:CC - Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

- Phase II acute pain program to initiate in September - Ended quarter with $50 million in cash and equivalents, providing over two years of runway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide pla...
ATE:CC - Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights

- Phase II acute pain program to initiate in early calendar Q4 2022 - Ended year with $55 million in cash and equivalents, providing over two years of runway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sul...

ATE:CC - Antibe Therapeutics Announces Amendment to Warrant Terms

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the " Company "), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “ Warrant Extensio...

ATE:CC - Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair o...
ATE:CC - Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary

- $6.5 million all-cash transaction, including milestone payments - Enables exclusive focus on drug pipeline Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer ...

ATE:CC - Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference b...

Previous 10 Next 10